Freyr GRI

Freyr GRI

Rechercher

Why Regulatory Intelligence Tools Are Becoming Essential for Global Life Sciences Organizations

The life sciences industry has always operated under strict regulatory oversight. However, today's regulatory environment is far more dynamic than it was even a decade ago. Health authorities across the globe continuously publish new regulations, revise existing guidance, introduce updated technical standards, and strengthen compliance expectations. For pharmaceutical companies, biotechnology...

2026-07-14 05:17:55

Suite de l'agenda

Why 2026 Is a Defining Year for Pharmaceutical Industry Regulations

The life sciences industry is entering a new phase of regulatory transformation. As healthcare innovation accelerates, regulatory authorities worldwide are introducing frameworks that encourage scientific advancement while strengthening compliance expectations. For pharmaceutical companies, medical device manufacturers, and cosmetics businesses, 2026 is proving to be a pivotal year. New...

2026-06-30 05:17:20

Suite de l'agenda

The Hidden Cost of Regulatory Delays: Why Life Sciences Organizations Are Turning to AI-Powered Intelligence

In the life sciences industry, delays are expensive. A delayed submission can postpone product approvals. A missed regulatory update can trigger compliance challenges. Slow responses to changing requirements can impact market access strategies and create operational disruptions. While organizations often focus on the direct costs of regulatory activities, the indirect costs of delayed decisions...

2026-06-08 08:43:30

Suite de l'agenda

How Regulatory Intelligence Consulting Improves Compliance and Accelerates Global Market Access

The global life sciences industry is facing increasing regulatory pressure as healthcare authorities continue to strengthen compliance requirements across pharmaceuticals, biotechnology, medical devices, cosmetics, and related sectors. Organizations operating in these industries must now manage evolving regulatory expectations while also maintaining innovation, product quality, and operational...

2026-05-29 09:40:13

Suite de l'agenda

What Does “Intentionally Added PFAS” Mean in Cosmetics?

Your Cosmetic Formulations Contain PFAS. The FDA Has Noticed. Have You? For years, PFAS in cosmetics was a background concern — something discussed in environmental circles, flagged occasionally by advocacy groups, but rarely treated as an urgent business issue by manufacturers. That era is over. The FDA has completed a structured review of intentionally added PFAS in cosmetic...

2026-05-28 11:07:44

Suite de l'agenda

What Does “Intentionally Added PFAS” Mean in Cosmetics?

Intentionally Added PFAS in Cosmetics: What Manufacturers Need to Know The FDA Has Been Paying Attention — And So Should You Per- and polyfluoroalkyl substances aren't new to cosmetic formulations. But the regulatory environment around them is changing fast, and a specific category is now at the center of that shift: intentionally added PFAS — substances deliberately selected by...

2026-05-28 06:04:23

Suite de l'agenda

OSHA Hazard Communication Standard (HCS): Explained

OSHA Hazard Communication Standard (HCS): What Every Workplace Needs to Know Compliance in chemical-handling workplaces doesn't begin with paperwork or labels. It begins with a clear understanding of the OSHA Hazard Communication Standard — and why it exists. What Is the OSHA Hazard Communication Standard? The Hazard Communication Standard (HCS) is a federal regulation established by the...

2026-05-28 04:58:07

Suite de l'agenda

Effective Strategies for Managing Regulatory Changes in Global Pharma Operations

The pharmaceutical industry operates in an environment where regulatory change is constant. Health authorities worldwide continuously update compliance requirements to improve patient safety, product quality, pharmacovigilance standards, and manufacturing practices. For pharmaceutical companies managing products across multiple countries, staying compliant with these evolving...

2026-05-19 11:44:05

Suite de l'agenda

Why Regulatory Intelligence Is Essential for Modern Pharmaceutical Companies

The pharmaceutical industry is evolving rapidly, and with that evolution comes increasing regulatory complexity. Companies today operate in a highly regulated global environment where compliance requirements change frequently across different markets, health authorities, and product categories. Regulatory affairs teams are expected to monitor evolving guidelines, manage product registrations,...

2026-05-12 05:00:50

Suite de l'agenda

Incorrect SDS Hazard Classification: Costs, Risks & Penalties

Why Getting Hazard Classification Wrong Is More Expensive Than You Think In many organisations, hazard classification in Safety Data Sheets (SDS) is often treated as a routine compliance activity — simply another requirement to complete during product launches or updates. However, with evolving EU CLP regulations and the addition of new hazard classes such as endocrine disruptors (ED),...

2026-05-11 12:16:14

Suite de l'agenda

Incorrect SDS Hazard Classification: Costs, Risks & Penalties

Why Getting Hazard Classification Wrong Is More Expensive Than You Think In many organisations, hazard classification in Safety Data Sheets (SDS) is often treated as a routine compliance activity — simply another requirement to complete during product launches or updates. However, with evolving EU CLP regulations and the addition of new hazard classes such as endocrine disruptors (ED),...

2026-05-11 11:38:25

Suite de l'agenda

Regulatory Intelligence for Medical Devices: Staying Ahead in a Constantly Changing Compliance Landscape

In the medical device industry, regulatory change is not occasional—it is constant. New guidelines, evolving standards, and shifting compliance expectations are released across global markets at an unprecedented pace. For organizations trying to keep up, the challenge is not just understanding regulations but staying ahead of them. This is why Regulatory Intelligence for Medical Devices...

2026-04-17 08:48:41

Suite de l'agenda

Plus